Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Rebecca A DentMafalda OliveiraSteven J IsakoffSeock-Ah ImMarc EspiéSibel BlauAntoinette R TanCristina SauraMatthew J WongchenkoNa XuDenise BradleySarah-Jayne ReillyAruna ManiSung-Bae Kimnull nullPublished in: Breast cancer research and treatment (2021)
Final OS results show a numerical trend favoring ipatasertib-paclitaxel and median OS exceeding 2 years with ipatasertib-paclitaxel. Overall, results are consistent with the reported PFS benefit; interpretation within biomarker-defined subgroups is complicated by small sample sizes and TNBC heterogeneity.